Compare STRIDES PHARMA SCIENCE with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs NATCO PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE NATCO PHARMA STRIDES PHARMA SCIENCE/
NATCO PHARMA
 
P/E (TTM) x 16.4 23.2 70.5% View Chart
P/BV x 1.0 3.5 29.1% View Chart
Dividend Yield % 0.5 1.0 49.5%  

Financials

 STRIDES PHARMA SCIENCE   NATCO PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
NATCO PHARMA
Mar-19
STRIDES PHARMA SCIENCE/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147849 135.1%   
Low Rs642557 115.3%   
Sales per share (Unadj.) Rs317.2573.8 55.3%  
Earnings per share (Unadj.) Rs7.8176.0 4.5%  
Cash flow per share (Unadj.) Rs25.1198.2 12.6%  
Dividends per share (Unadj.) Rs2.006.25 32.0%  
Dividend yield (eoy) %0.20.9 25.1%  
Book value per share (Unadj.) Rs274.3842.7 32.5%  
Shares outstanding (eoy) m89.5036.50 245.2%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.81.2 230.2%   
Avg P/E ratio x114.04.0 2,854.7%  
P/CF ratio (eoy) x35.73.5 1,006.5%  
Price / Book Value ratio x3.30.8 391.0%  
Dividend payout %25.53.6 717.9%   
Avg Mkt Cap Rs m80,05825,660 312.0%   
No. of employees `0002.55.0 50.6%   
Total wages/salary Rs m4,3413,559 122.0%   
Avg. sales/employee Rs Th11,325.84,225.3 268.0%   
Avg. wages/employee Rs Th1,731.4718.0 241.1%   
Avg. net profit/employee Rs Th280.11,295.9 21.6%   
INCOME DATA
Net Sales Rs m28,39420,945 135.6%  
Other income Rs m9411,302 72.2%   
Total revenues Rs m29,33422,247 131.9%   
Gross profit Rs m3,9657,948 49.9%  
Depreciation Rs m1,540810 190.2%   
Interest Rs m1,962193 1,016.8%   
Profit before tax Rs m1,4038,247 17.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,823 5.3%   
Profit after tax Rs m7026,424 10.9%  
Gross profit margin %14.037.9 36.8%  
Effective tax rate %6.922.1 31.4%   
Net profit margin %2.530.7 8.1%  
BALANCE SHEET DATA
Current assets Rs m24,83623,472 105.8%   
Current liabilities Rs m18,9937,287 260.6%   
Net working cap to sales %20.677.3 26.6%  
Current ratio x1.33.2 40.6%  
Inventory Days Days7192 77.0%  
Debtors Days Days11388 128.6%  
Net fixed assets Rs m34,28918,648 183.9%   
Share capital Rs m895365 245.2%   
"Free" reserves Rs m23,65134,525 68.5%   
Net worth Rs m24,54630,760 79.8%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43743,031 152.1%  
Interest coverage x1.743.7 3.9%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 89.1%   
Return on assets %4.115.4 26.5%  
Return on equity %2.920.9 13.7%  
Return on capital %6.927.4 25.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69711,536 136.1%   
Fx outflow Rs m7352,939 25.0%   
Net fx Rs m14,9628,597 174.0%   
CASH FLOW
From Operations Rs m1,8716,688 28.0%  
From Investments Rs m5,826-6,122 -95.2%  
From Financial Activity Rs m-10,157-509 1,995.5%  
Net Cashflow Rs m-2,61566 -3,962.0%  

Share Holding

Indian Promoters % 27.7 52.0 53.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 37.8 7.8 482.1%  
FIIs % 8.6 16.6 51.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 26.0 99.6%  
Shareholders   56,241 25,395 221.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   CADILA HEALTHCARE  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 429 Points Higher; Auto and IT Stocks Rally(Closing)

Indian share markets extended gains for the second consecutive day and ended on a strong note, tracking gains in Asian peers and Wall Street.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

This is How You Should Trade Intraday(Fast Profits Daily)

Jun 19, 2020

In this video, I'll show you how to trade the market intraday like a professional trader.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 2, 2020 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - ALKEM LABORATORIES COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS